Efficiency of the EmERGE Pathway to provide continuity of care for Spanish people living with medically stable HIV

Blanco, 2020, COVID-19 in patients with HIV: clinical case series, Lancet HIV, 10.1016/S2352-3018(20)30111-9 Beck, 2018, Developing and implementing national health identifiers in resource limited countries: why, what, who, when and how?, Global Health Act, 11 Taylor, 2019, Effectiveness of text messaging interventions on prevention, detection, treatment, and knowledge outcomes for sexually transmitted infections (STIs)/HIV: a systematic review and meta-analysis, Syst Rev, 8, 12, 10.1186/s13643-018-0921-4 Cooper, 2017, mHealth interventions to support self-management in HIV: a systematic review, Open AIDS J, 11, 119, 10.2174/1874613601711010119 Hyle, 2014, HIV tuberculosis, and non-communicable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care?, J Acquir Immune Defic Syndr, 67, S87, 10.1097/QAI.0000000000000254 IAM Newswire, TeleMedicine – one of the first COVID-19 By-Products, May 19, 2020. https://iamnewswire.com/2020/05/19/telemedicine-one-of-the-first-covid-19-by-products/?mod=article_inline [accessed 19.8.20]. Cheney, 2020, How to use telehealth in cancer care during the coronavirus pandemic and beyond, HealthLeaders World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva, World Health Organization 2015. http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1 [accessed 10.11.20]. Marcus, 2016, Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care, J Acquir Immune Defic Syndr, 73, 39, 10.1097/QAI.0000000000001014 Autenrieth, 2018, Global and regional trends of people living with HIV aged 50 and over: estimates and projections for 2000–2020, PLOS ONE, 13, e0207005, 10.1371/journal.pone.0207005 Althoff, 2016, HIV and ageing: improving quantity and quality of life, Curr Opin HIV AIDS, 11, 527, 10.1097/COH.0000000000000305 Shah, 2018, Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis, Circulation, 138, 1100, 10.1161/CIRCULATIONAHA.117.033369 Chausa P, Gárate FJ, Cáceres C, Wallitt E, Whetham J and Gómez EJ. and the EmERGE Consortium. EmERGE Platform: A New mHealth Solution for People Living with HIV. In: Henriques J., Neves N., de Carvalho P. (eds) XV Mediterranean Conference on Medical and Biological Engineering and Computing – MEDICON 2019. MEDICON 2019. IFMBE Proceedings, vol 76. Springer, Cham. https://link.springer.com/chapter/10.1007%2F978-3-030-31635-8_99 [accessed 10.11.20]. Waldrop, 2016, Stable patients and patients with advanced disease: consensus definitions to support sustained scale up of antiretroviral therapy, Trop Med Int Health, 21, 1124, 10.1111/tmi.12746 Beck, 2016, Protecting the confidentiality and security of personal health information in low- and middle-income countries in the era of the SDGs and big-data, Global Health Act, 10.3402/gha.v9.32089 Whitten, 2002, Systematic review of cost effectiveness studies of telemedicine interventions, BMJ, 324, 1434, 10.1136/bmj.324.7351.1434 Hailey, 2005, The need for cost-effectiveness studies in telemedicine, J Telemed Telecare, 10.1177/1357633X0501100801 de Jongh, 2012, Mobile phone messaging for facilitating self-management of long-term illnesses, Cochrane Database Syst Rev, 10.1002/14651858.CD007459.pub2 León, 2011, New multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study, PLoS One, 6, e14515, 10.1371/journal.pone.0014515 UNAIDS. Manual for costing HIV facilities and services. Geneva, Switzerland, 23rd May 2011. http://www.unaids.org/en/media/unaids/contentassets/documents/document/2011/20110523_manual_costing_HIV_facilities_en.pdf [accessed 10.11.20]. UNAIDS. Workbook for the collection of cost information on HIV facilities and services. Geneva, Switzerland, 23rd May 2011. http://www.unaids.org/en/media/unaids/contentassets/documents/document/2011/20110523_workbook_cost_info_en.pdf [accessed 10.11.20]. Beck EJ, Yfantopoulos P, Mandalia S. EU Deliverable 3.3 Costs and Unit Costs for EmERGE clinical sites, 29th April 2020. EU Grant Agreement No: 643736. Beck EJ, Mandalia S, Yfantopoulos P. EU Deliverable 3.4 Cost-efficiency of the mHealth Pathway at the Five EmERGE Sites. 29th April 2020. EU Grant Agreement No: 643736. West, 2007 SAS Version 9.4. Cary, NC: SAS Institute Inc; 2014. Beck, 2004, The cost-effectiveness of HAART, Canada 1991–2001, AIDS, 18, 2411 Badri, 2006, Cost-effectiveness of highly active antiretroviral therapy in South Africa, PLoS Med, 3, e4, 10.1371/journal.pmed.0030004 Mandalia, 2010, Rising population cost for treating people living with HIV in the UK, 1997–2013, PLoS ONE, 5, e15677, 10.1371/journal.pone.0015677 Hibbard, 2005, Development and testing of a short form of the patient activation measure, Health Serv Res, 40, 1918, 10.1111/j.1475-6773.2005.00438.x Duracinsky, 2012, The development of PROQOL-HIV: an international instrument to assess the health-related quality of life of persons living with HIV/AIDS, J Acquir Immune Defic Syndr, 59, 498, 10.1097/QAI.0b013e318245cafe Wikipedia. Incremental cost-effectiveness ratio https://en.wikipedia.org/wiki/Incremental_cost-effectiveness_ratio [accessed 10.11.20]. Beck EJ, Mandalia S, Yfantopoulos P, Lean A, Merino MJ, Garcia F et al. on behalf of the EmERGE Consortium Ensuring Continuity of Care for People living with HIV in Five European Countries: the efficacy of the EmERGE Platform P117, HIV Glasgow 2020, Virtual Meeting 5-8 October 2020, Glasgow, Scotland. Marent B, Henwood F, Darking M EU Deliverable 2.3 Final Evaluation Report: Best practice in co-design and user (clinician and patient) involvement across study sites. 28th April 2020. EU Grant Agreement No: 643736. Jones, 2020 Public Health England: Guidance, Before-and-after study: comparative studies. Gov.UK, 30 January 2020. https://www.gov.uk/guidance/before-and-after-study-comparative-studies [accessed 10.11.20]. Rivero, 2018, Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults, Enferm Infecc Microbiol Clin, 36, 268, 10.1016/j.eimc.2017.04.002 Beck, 2019, Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?, Global Health Act, 12, 1586317, 10.1080/16549716.2019.1586317 Beck, 2012, Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004–2008, PLoS ONE, 7, e47376, 10.1371/journal.pone.0047376 Lopez-Bastida, 2009, The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain, BMC Health Serv Res, 9, 55, 10.1186/1472-6963-9-55 Trapero-Bertran, 2014, Economic impact of HIV/AIDS: a systematic review in five European countries, Health Econ Rev, 4, 15, 10.1186/s13561-014-0015-5 Hall, 2014, For telehealth to succeed, privacy and security risks must be identified and addressed, Health Aff (Millwood), 33, 216, 10.1377/hlthaff.2013.0997 UNAIDS: The Privacy, Confidentiality and Security Assessment Tool: Protecting personal health information. Geneva 14th February 2019. http://www.unaids.org/en/resources/documents/2019/confidentiality_security_assessment_tool [accessed 10.11.20]. Catalani, 2013, mHealth for HIV treatment & prevention: a systematic review of the literature, Open AIDS J, 7, 17, 10.2174/1874613620130812003 de la Torre-Díez, 2015, Cost-utility and cost-effectiveness studies of telemedicine, electronic, and mobile health systems in the literature: a systematic review, Telemed e-Health, 21, 81, 10.1089/tmj.2014.0053 Sarabi, 2016, The effectiveness of mobile phone text messaging in improving medication adherence for patients with chronic diseases: a systematic review, Iran Red Crescent Med J, 18, e25183 Kaplan, 2006, Can the ubiquitous power of mobile phones be used to improve health outcomes in developing countries?, Glob Health, 2, 10.1186/1744-8603-2-9 Govindasamy, 2014, Interventions to improve or facilitate linkage to or retention in pre-ART (HIV) care and initiation of ART in low- and middle-income settings – a systematic review, JIAS, 10.7448/IAS.17.1.19032 Thirumurthy, 2012, M-health for health behaviour change in resource-limited settings: applications to HIV care and beyond, Bull World Health Organ, 90, 390, 10.2471/BLT.11.099317 Iribarren, 2017, What is the economic evidence for mHealth? A systematic review of economic evaluations of mHealth solutions, PLOS ONE, 12, e0170581, 10.1371/journal.pone.0170581 Rout, 2019, Can telemedicine initiative be an effective intervention strategy for improving treatment compliance for pediatric HIV patients: evidences on costs and improvement in treatment compliance from Maharashtra, India, PLOS ONE, 14, e0223303, 10.1371/journal.pone.0223303 Demena, 2020, A systematic review of mobile phone interventions (SMS/IVR/Calls) to improve adherence and retention to antiretroviral treatment in low and middle-income countries, Aids Patient Care STDS, 34, 10.1089/apc.2019.0181 Wright, 2020, Remote treatment delivery in response to the COVID-19 pandemic, Psychother Psychosom, 89, 130, 10.1159/000507376 Humer, 2020, Provision of psychotherapy during the COVID-19 Pandemic among Czech, German and Slovak Psychotherapists, Int J Environ Res Public Health, 17, 4811, 10.3390/ijerph17134811 Allied Market Research. COVID-19 Impact on mHealth Market Size to hit $230 billion by 2027, Top Prominent Players: Bayer Healthcare., Boston Scientific Corporation. Press Release 27-7-2020. https://www.openpr.com/news/2098085/covid-19-impact-on-mhealth-market-size-to-hit-230-billion [accessed 10.11.20]. WHO/International Bank for Reconstruction and Development/The World Bank. Tracking universal health coverage: 2017 global monitoring report, 2017. http://pubdocs.worldbank.org/en/193371513169798347/2017-global-monitoring-report.pdf [accessed 10.11.20].